好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Virtual Multiple Sclerosis Clinics During a Global Pandemic: the Patients’ Perspective
Multiple Sclerosis
MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)
234

To assess patient satisfaction with virtual telephone clinics during the pandemic, influencing factors on this, and future utility.

Covid-19 has had a significant impact on all health services. Within our service, all face-to-face neurology clinics were cancelled from March 20th 2020, due to increasing clinical demands, staff redeployment and exposure risk to patients. Telephone reviews were initiated as an alternative and the Multiple sclerosis (MS) team embraced this method to provide continuity of care.

We developed a postal questionnaire for patients receiving telephone reviews from an MS consultant or clinical fellow, March to July 2020. Ultimately, 635 anonymised questionnaires were posted to patients. Data analysis deployed both quantitative and qualitative methods.

To date, 254 (40%) patient questionnaires have been returned, mean age 50 years, 72% female, and 86% having an EDSS <7.0. Using a numerical rating scale (0-10, 10 = completely satisfied), 96% of patients reported an overall satisfaction score of ≥7. For 99% of patients, they found interaction to be sensitive and caring over telephone. Most patients were content with call duration (96%) and reported ample opportunity to ask questions (99%). During the pandemic, 89% of patients preferred the telephone call to a face-to-face appointment. For 47% of patients, there was clear preference for telephone review moving forward, rising to 55% among both wheelchair-using patients and those living more than fifty miles from clinic. 54% of patients felt that video call would further improve virtual clinical review.

 

During the COVID-19 pandemic, satisfaction is high with the telephone approach to MS clinical consultation. Although mixed, and influenced by level of disability and distance from the clinic, a significant body of patient opinion supports telephone calls remaining part of the clinic experience in the post-COVID era. This may lead to more efficient resource utilisation and minimise inconvenience and stress for patients.

Authors/Disclosures
Stephen J. Ramsay, MB (UK) (Royal Victoria Hospital, Belfast Health and Social Care Trust)
PRESENTER
Dr. Ramsay has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Jon D. McKee, MBBS (Craigavon Hospital) Dr. McKee has nothing to disclose.
Fiona Kennedy, MB, Bch, BAO Dr. Kennedy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Kennedy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Kennedy has received personal compensation in the range of $500-$4,999 for serving as a Meeting chair with Neuraxpharm. Dr. Kennedy has received personal compensation in the range of $500-$4,999 for serving as a Meeting chair with Roche. Dr. Kennedy has received personal compensation in the range of $0-$499 for serving as a Meeting chair with Merck. Dr. Kennedy has received personal compensation in the range of $500-$4,999 for serving as a Conference delegate with Sanofi. Dr. Kennedy has received personal compensation in the range of $500-$4,999 for serving as a Conference delegate with Novartis. Dr. Kennedy has received personal compensation in the range of $500-$4,999 for serving as a Conference delegate with Roche.
Aidan G. Droogan, BSc, MBB (Belfast HSC Trust (RVH)) Dr. Droogan has nothing to disclose.
Stella E. Hughes, MD Dr. Hughes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Hughes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Hughes has received personal compensation in the range of $500-$4,999 for serving as a Meeting Chair with Merck. Dr. Hughes has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Biogen. Dr. Hughes has received personal compensation in the range of $500-$4,999 for serving as a Meeting Chair with Roche. Dr. Hughes has received personal compensation in the range of $500-$4,999 for serving as a Conference Delegate with Roche.
Gavin V. McDonnell, MD (Belfast Trust) Dr. McDonnell has nothing to disclose.